Literature DB >> 11101096

Multimodality therapy for the treatment of muscle-invasive bladder cancer.

S A Thurman1, T L DeWeese.   

Abstract

In the United States, local management of muscle-invasive bladder cancer largely remains radical cystectomy with urinary diversion. However, this approach is undergoing transition. Organ-preserving approaches using a combination of multiple modalities have been successfully applied to the management of several types of cancer and clearly play an important role in the management of muscle-invasive bladder cancer as well. Since the 1980s, several single and multi-institutional trials have confirmed that a combined modality organ-preserving approach (chemotherapy administered in conjunction with radiation) consistently confers equivalent overall survival compared with survival following radical cystectomy. These trials are very encouraging and allow organ preservation to be considered an appropriate therapeutic option for patients with muscle-invasive bladder cancer.

Entities:  

Mesh:

Year:  2000        PMID: 11101096

Source DB:  PubMed          Journal:  Semin Urol Oncol        ISSN: 1081-0943


  2 in total

1.  Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.

Authors:  Hideaki Miyake; Kazuki Yamanaka; Mototsugu Muramaki; Isao Hara; Martin E Gleave
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

2.  Expression of transcription factors snail, slug, and twist in human bladder carcinoma.

Authors:  Qinchao Yu; Kejun Zhang; Xinsheng Wang; Xiangping Liu; Zemi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2010-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.